What Chemo-Free Immunotherapy Combos Have Potential in Indolent Lymphomas?

Commentary
Video

Lorenzo Falchi, MD, highlighted the phase 1b/2 EPCORE NHL-2 and phase 1 BP41072 trials as prominent trials evaluating novel immunotherapy combinations in indolent lymphoma.

Lorenzo Falchi, MD, gave a presentation titled “Novel Immunotherapy Combinations in Indolent Lymphoma” at the Society of Hematological Oncology (SOHO) 2025 Annual Meeting. At the conference, he spoke with CancerNetwork® regarding the current landscape of combination therapies in indolent lymphomas.1

When prompted about some of the most stand-out therapies, Falchi, an oncologist and hematologist specializing in lymphoma at the Memorial Sloan Kettering Cancer Center, highlighted several therapies. The first mentioned was the phase 1b/2 EPCORE NHL-2 trial (NCT04663347), which evaluated epcoritamab (Epkinly) in combination with various other standard-of-care agents, including rituximab (Rituxan), lenalidomide, and bendamustine, in patients with B-cell non-Hodgkin lymphoma.2

In EPCORE NHL-2, he noted that high levels of complete responses (CRs) and progression-free survival were achieved.

Another mentioned trial was the phase 1 BP41072 trial (NCT04077723), which is evaluating the safety, tolerability, and efficacy of various regimens containing englumafusp alfa [CD19-4-1BBL] in patients with relapsed/refractory non-Hodgkin lymphoma.3 Notably, 79% of the patients with follicular lymphoma enrolled in the trial achieved a CR.

Transcript:

Lymphoma therapy, in general, is hardly ever a one-man show. It’s hardly ever a monotherapy, except for CAR T-cell therapy. Some of the more efficacious and powerful treatments for lymphoma in general, [and in] follicular lymphoma, are combinations of multiple anti-lymphoma drugs. This is also true for bispecific antibodies, and this is what I tried to outline in my presentation. For example, lenalidomide, which is an immunomodulating drug, has been a natural partner for bispecific antibodies alone or with rituximab, and the results with combined lenalidomide and bispecifics have been promising. Most patients achieve a CR.

In the study testing epcoritamab with rituximab and lenalidomide, we enrolled 111 patients. This is a large international…trial where we saw that 87% of the patients achieved a CR, and at 21 months of follow-up, 80% of the patients were progression-free. In addition to that, if one looks at the minimal residual disease [MRD]-negative response of patients who cleared their MRD, their chance of response and progression-free survival was even higher. This data suggested that the types of responses and the depth of responses with this combination were promising.

Other combinations have been tested. One that I am particularly excited about is with what’s called costimulatory bispecific antibodies—it’s a bispecific-bispecific duet. The first bispecific, the primary bispecific, was glofitamab [Columvi], and the second bispecific, the adjuvant or secondary bispecific, is the costimulatory…englumafusp alfa. It’s a promising drug because it attaches to the lymphoma cells, like the primary antibody, and to the T cell, delivering signal 2 to the T cell, and that boosts the T-cell activation and the ability to kill off the lymphoma cells.

That’s a beautiful theoretical concept, but the question was, “Is it going to work in clinical practice?” There has been a large first-in-human phase 1 trial internationally, demonstrating that 79% of the 24 enrolled patients with follicular lymphoma had a CR, and most of them held that response at a relatively long follow-up of almost 36 months. We have a sense that we can top the results of single-agent bispecific antibodies in multiple ways.

References

  1. Falchi, L. Novel immunotherapy combinations in indolent lymphoma. Presented at the Society of Hematological Oncology 2025 Annual Meeting; September 2-6, 2025; Houston, TX.
  2. Safety and efficacy trial of epcoritamab combinations in subjects with B-cell non-Hodgkin lymphoma (B-NHL) (EPCORE™ NHL-2). ClinicalTrials.gov. Updated September 3, 2025. Accessed September 22, 2025. https://tinyurl.com/24zaf59p
  3. A study to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of englumafusp alfa in combination with obinutuzumab and in combination with glofitamab following a pre-treatment dose of obinutuzumab in participants with relapsed/​refractory B-cell non-Hodgkin’s lymphoma. ClinicalTrials.gov. Updated September 5, 2025. Accessed September 5, 2025. https://tinyurl.com/muedr6bt
Recent Videos
The clinical adoption of twice-daily accelerated radiotherapy has been limited in North America despite improved outcomes, according to Bin Gui, MD.
The development of multimodal biomarkers may help predict response to immunotherapy among patients with melanoma and other malignancies.
Patients with high-risk markers may especially benefit from the addition of daratumumab to lenalidomide as maintenance therapy for NDMM.
A machine learning method for scoring tumor-infiltrating lymphocytes may address variability in pathologist measurements.
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
Related Content